Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC

Clinical trial NCT05469061 · UNKNOWN

Trial details

NCT number: NCT05469061
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Esophageal Squamous Cell Carcinoma Locally Advanced Carcinoma

Start date: 2022-01-01
Primary completion: 2022-08-01
Enrollment: 17

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.